FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246578052> ?p ?o ?g. }

• W4246578052 endingPage "9720" @default.
• W4246578052 startingPage "9720" @default.
• W4246578052 abstract "9720 Background: Since characterization of BRCA1 and BRCA2 in 1994 1995 resp. genetic testing of these genes is possible. Germline mutations in these genes are the most common reason for hereditary breast and ovarian cancer. Methods: Since December 1996 testing of BRCA1 or BRCA2 mutations is implemented in twelve university hospitals all over Germany granted by the German Cancer Aid (Deutsche Krebshilfe). After detailed counseling by a gynecologist, a psycho-oncologist and a human geneticist genetic testing is offered to those family members already laid up with breast or ovarian cancer or those who are on risk for hereditary breast or ovarian cancer. Families are grouped into different risk categories: A=three or more family members suffering from breast cancer with at least two of them becoming deseased premenopausally or male breast cancer, B=families with breast and/or ovarian cancer or more family member having breast and ovarian cancer, C=two family members suffering from breast cancer with at least one of them becoming diseased premenopausally or only one woman with bilateral breast cancer first diseased in an age of ≤ 40 years, D=two and more women suffering from postmenopausal breast cancer and E=only one woman with early onset of breast cancer (≤ 35 years). By now more than 1100 persons have been tested. These are the results of an interim analysis of 2755 (hereof 1077 tested) cancer patients out of 737 families. Results: The distribution of the families in the previously described categories was A=34,5%, B=27,1%, C=27,5%, D=4,3% and E=4,0%. In 44% of all families a mutation in BRCA1 or 2 was found but 56% of all families were found BRCA1/2 negative. Looking to all detecte BRCA1-mutations the major percentage was verified in B-category (53,5%) and the A-category (37,6%) and only 6% in C, 3% E and none in D families. BRCA2-mutations are mostly find in A (57,5%) and B families (26,0%) and less in C (12,3%), D(2,7%) and E families (1,4%). On the other hand 76,8% C, 77,4% D and 82,8% E families were tested BRCA1/2 negativ. Conclusions: According to our results genetic testing is indicated in families with either breast and ovarian cancer or multiple premenopausal breast cancer. No significant financial relationships to disclose." @default.
• W4246578052 created "2022-05-12" @default.
• W4246578052 creator A5002771493 @default.
• W4246578052 creator A5012626507 @default.
• W4246578052 creator A5013546450 @default.
• W4246578052 creator A5014371582 @default.
• W4246578052 creator A5017327623 @default.
• W4246578052 creator A5018772008 @default.
• W4246578052 creator A5030749614 @default.
• W4246578052 creator A5033967470 @default.
• W4246578052 creator A5034786303 @default.
• W4246578052 creator A5036223271 @default.
• W4246578052 creator A5038665947 @default.
• W4246578052 creator A5039378965 @default.
• W4246578052 creator A5042697041 @default.
• W4246578052 creator A5044648051 @default.
• W4246578052 creator A5045303149 @default.
• W4246578052 creator A5045660631 @default.
• W4246578052 creator A5050404657 @default.
• W4246578052 creator A5051410904 @default.
• W4246578052 creator A5051437624 @default.
• W4246578052 creator A5053355271 @default.
• W4246578052 creator A5058395446 @default.
• W4246578052 creator A5059882861 @default.
• W4246578052 creator A5060054890 @default.
• W4246578052 creator A5060440840 @default.
• W4246578052 creator A5060709706 @default.
• W4246578052 creator A5076463448 @default.
• W4246578052 creator A5085725989 @default.
• W4246578052 creator A5086246751 @default.
• W4246578052 creator A5086375653 @default.
• W4246578052 creator A5090036649 @default.
• W4246578052 creator A5090676140 @default.
• W4246578052 date "2004-07-15" @default.
• W4246578052 modified "2023-09-27" @default.
• W4246578052 title "Indications for BRCA1 and BRCA2 mutation testing in hereditary breast and ovarian cancer families" @default.
• W4246578052 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.9720" @default.
• W4246578052 hasPublicationYear "2004" @default.
• W4246578052 type Work @default.
• W4246578052 citedByCount "0" @default.
• W4246578052 crossrefType "journal-article" @default.
• W4246578052 hasAuthorship W4246578052A5002771493 @default.
• W4246578052 hasAuthorship W4246578052A5012626507 @default.
• W4246578052 hasAuthorship W4246578052A5013546450 @default.
• W4246578052 hasAuthorship W4246578052A5014371582 @default.
• W4246578052 hasAuthorship W4246578052A5017327623 @default.
• W4246578052 hasAuthorship W4246578052A5018772008 @default.
• W4246578052 hasAuthorship W4246578052A5030749614 @default.
• W4246578052 hasAuthorship W4246578052A5033967470 @default.
• W4246578052 hasAuthorship W4246578052A5034786303 @default.
• W4246578052 hasAuthorship W4246578052A5036223271 @default.
• W4246578052 hasAuthorship W4246578052A5038665947 @default.
• W4246578052 hasAuthorship W4246578052A5039378965 @default.
• W4246578052 hasAuthorship W4246578052A5042697041 @default.
• W4246578052 hasAuthorship W4246578052A5044648051 @default.
• W4246578052 hasAuthorship W4246578052A5045303149 @default.
• W4246578052 hasAuthorship W4246578052A5045660631 @default.
• W4246578052 hasAuthorship W4246578052A5050404657 @default.
• W4246578052 hasAuthorship W4246578052A5051410904 @default.
• W4246578052 hasAuthorship W4246578052A5051437624 @default.
• W4246578052 hasAuthorship W4246578052A5053355271 @default.
• W4246578052 hasAuthorship W4246578052A5058395446 @default.
• W4246578052 hasAuthorship W4246578052A5059882861 @default.
• W4246578052 hasAuthorship W4246578052A5060054890 @default.
• W4246578052 hasAuthorship W4246578052A5060440840 @default.
• W4246578052 hasAuthorship W4246578052A5060709706 @default.
• W4246578052 hasAuthorship W4246578052A5076463448 @default.
• W4246578052 hasAuthorship W4246578052A5085725989 @default.
• W4246578052 hasAuthorship W4246578052A5086246751 @default.
• W4246578052 hasAuthorship W4246578052A5086375653 @default.
• W4246578052 hasAuthorship W4246578052A5090036649 @default.
• W4246578052 hasAuthorship W4246578052A5090676140 @default.
• W4246578052 hasConcept C104317684 @default.
• W4246578052 hasConcept C121608353 @default.
• W4246578052 hasConcept C126322002 @default.
• W4246578052 hasConcept C13514818 @default.
• W4246578052 hasConcept C143998085 @default.
• W4246578052 hasConcept C2776738285 @default.
• W4246578052 hasConcept C2780194787 @default.
• W4246578052 hasConcept C2780427987 @default.
• W4246578052 hasConcept C2780673598 @default.
• W4246578052 hasConcept C2781179581 @default.
• W4246578052 hasConcept C29456083 @default.
• W4246578052 hasConcept C501734568 @default.
• W4246578052 hasConcept C530470458 @default.
• W4246578052 hasConcept C54355233 @default.
• W4246578052 hasConcept C71924100 @default.
• W4246578052 hasConcept C80227256 @default.
• W4246578052 hasConcept C86803240 @default.
• W4246578052 hasConceptScore W4246578052C104317684 @default.
• W4246578052 hasConceptScore W4246578052C121608353 @default.
• W4246578052 hasConceptScore W4246578052C126322002 @default.
• W4246578052 hasConceptScore W4246578052C13514818 @default.
• W4246578052 hasConceptScore W4246578052C143998085 @default.
• W4246578052 hasConceptScore W4246578052C2776738285 @default.
• W4246578052 hasConceptScore W4246578052C2780194787 @default.
• W4246578052 hasConceptScore W4246578052C2780427987 @default.
• W4246578052 hasConceptScore W4246578052C2780673598 @default.

• next